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To coin a phrase: did the selective inversion approach demonstrate bias in the results of studies 
using routinely collected data? 
Jonathan Sterne, Professor of Medical Statistics and Epidemiology, NIHR Bristol Biomedical Research 
Centre, Department of Population Health Sciences, Bristol Medical School, University of Bristol, 
Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK. 
Acknowledgement: This commentary draws on comments made by the late Professor Doug Altman, 
in his capacity as BMJ statistical editor. 
Standfirst: Selective inversion (“coining”) of the direction of comparisons led to strong 
disagreements over the validity of a paper examining bias in studies of interventions based on 
routinely collected data, and a correction published in this week’s BMJ. 
In early 2016 BMJ published a paper by Hemkens et al. entitled “Agreement of treatment effects for 
mortality from routinely collected data and subsequent randomized trials: meta-epidemiological 
survey”.1 This study used a novel design: the authors identified observational studies based on 
routinely collected data (RCD) that were performed before any randomized controlled trial (RCT) on 
the same clinical question, reported on all-cause mortality, and used a propensity score-based 
analysis to control confounding. The authors identified 16 RCD studies for which results from RCTs 
were subsequently reported. The main result was: “Overall, RCD studies showed significantly more 
favorable mortality estimates by 31% than subsequent trials (summary relative odds ratio [ROR] 1.31 
(95% CI 1.03 to 1.65; I2=0%)).” The authors also reported that “Confidence intervals in nine (56%) 
RCD studies did not include the RCT effect estimate.” They concluded that “studies that use 
routinely collected health data frequently do not agree with subsequent randomized trials” and that 
“the emerging pattern was that RCD studies systematically and substantially overestimated the 
mortality benefits of medical treatments compared with subsequent trials investigating the same 
question”. 
In August 2016 Franklin et al. submitted to BMJ a paper that criticised the methods used by 
Hemkens et al. After BMJ invited these authors to submit their comments as a rapid response rather 
than a separate paper, the work was published in Epidemiological Methods.2 Hemkens et al. had 
“inverted the RCD effect estimates where necessary so that each RCD study indicated an odds ratio 
less than 1”1. Their aim was to overcome the problem that some of the pairs compared two active 
interventions, so that the choice of direction of comparison was arbitrary. Franklin et al. showed 
that, under reasonable assumptions, the selective inversion approach employed by Hemkens et al. 
will lead the average ROR across studies to be greater than 1, even if there is no systematic 
difference between results from RCD studies and those from subsequent RCTs. This is because the 
sampling error in the OR for the RCD study is related both to the ROR and whether the OR is greater 
than 1 and so is inverted. 
Publication of the paper by Franklin et al. was noted in a rapid response posted on bmj.com by Dr 
Merino (BMJ US Research Editor) in August 2017. In September 2017 Hemkens et al. posted a 
further rapid response that dismissed the arguments and analyses of Franklin et al. as “flawed and 
misleading”. In October 2017 Franklin et al. responded that Hemkens et al. had not addressed the 
core statistical problem with their analyses. In November 2017 Dr Merino acknowledged receipt of a 
letter calling for retraction of the paper by Hemkens et al. Further comments by these authors and 
others were posted in a series of rapid responses on bmj.com. 
Hemkens et al. argued that their selective inversion approach, which they described as “coining”, 
was reasonable because they had taken the perspective of clinicians facing new evidence, having no 
randomized trials, and having to decide whether they use a new promising treatment. A counter-
argument is that, regardless of the clinical question being addressed, an appropriate method should 
result in an average ROR of 1 (corresponding to results in the two types of study being the same), in 
the absence of systematic differences between RCDs and RCTs. The “coining” approach has been 
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used in a number of publications, dating back at least to 20053. It seems possible that the bias that 
was demonstrated by Franklin et al. affected some of these publications.  
Extensive discussions, both on bmj.com and between Hemkens et al. and BMJ editors and reviewers, 
have now led to publication of a correction to the paper by Hemkens et al.4 These authors now 
present revised analyses that avoid selective inversion, either by restriction to comparisons of an 
active treatment with a control that did not receive this treatment, or by classifying treatments as 
“control” if they represented the established treatment or that shown in RCTs to work in the 
relevant indication. Detailed justifications for these classifications are provided in the correction. In 
general, the conclusions from the re-analyses are not greatly changed compared with the original 
paper. Some of the estimated RORs move further away from the null value of 1, while some of the 
confidence intervals become wider. In a combined analysis of the 15 clinical questions for which a 
direction could be chosen, the ROR was 1.38 (95% CI 1.09-1.74, I2=0%). The similarity of these results 
to those of the original study is because the direction of the results was recoded for only three. 
Results of RCD studies can be affected by both confounding and by other biases that are avoided in 
high quality RCTs. Randomization, providing that it is properly done, protects against confounding 
bias (other than through chance differences between intervention and control that are accounted 
for in the 95% confidence interval for the result)5. Even the most ardent advocates of RCD studies 
would agree that it is not always possible to control confounding (whether using propensity scores, 
as in the RCD studies considered by Hemkens et al., or any other method). The rapid response by 
Suisa et al. on 1 April 2016 identified additional biases (such as immortal time bias) that may have 
affected results of particular RCDs included in the study of Hemkens et al. It seems implausible that 
the true value of the ROR for each of the comparisons made by Hemkens et al. is 1, given that results 
of each RCD and each RCT will be at differing risks of bias. However, the magnitude and direction of 
of bias is likely to vary between studies and settings, leading to increases in between-study 
heterogeneity.6 
Hemkens et al. are to be congratulated on their novel study design, and their attempt to quantify 
differences between results of RCD studies and subsequently published RCTs. It is desirable, as they 
note in their correction, that their findings are replicated in a new study. Such a study should have a 
pre-specified analysis plan, with classification of “experimental” and “control” interventions based 
on clear rules and classified blind to the direction and magnitude of the difference between the 
results of the RCD and RCT. The revised analyses presented in the correction by Hemkens et al. were 
inevitably post hoc, and the need for clear criteria is illustrated by the study of on-pump (with 
cardiopulmonary bypass [CPB]) versus off-pump (without CPB) cardiac surgery by Karthik et al.7 
Hemkens et al. have changed the direction of comparison to consider off-pump surgery as control. 
However, it would seem more appropriate to have considered off-pump cardiac surgery as the new 
approach: Karthik et al. stated “In the last 15 years, CABG without CPB has developed into a viable 
alternative to on-pump CABG”. 
I have some areas of disagreement with the correction by Hemkens et al. Most importantly, they 
continue to describe the difference between the analyses that are and are not based on selective 
inversion as related to the clinical question of interest. Franklin et al demonstrated the selective 
inversion approach to be biased: it should not be used in future analyses of empirical studies. 
Second, the similarity of the results of the re-analysis with those in the original paper does not seem 
“remarkable”, given that the direction of comparison was changed for few RCD-RCT pairs.  
Third, Hemkens et al. reported on the proportion of RCD-RCT pairs for which the confidence interval 
for the RCD estimate did not include the estimated effect from RCTs: “in more than half of cases 
(nine of 16; 56%), the confidence intervals of the RCD based estimate did not include the mortality 
effect found in subsequent randomized trial evidence”, and concluded that “studies that use 
routinely collected health data frequently do not agree with subsequent randomized trials”. 
However, the precision of estimates based on RCTs was often much less than the precision of 
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estimates based on RCD studies. There is only a small probability that an imprecisely estimated RCT 
effect lies within the 95% CI for a precisely estimated RCD effect: see for example the comparison of 
hemodialysis with peritoneal dialysis in renal replacement therapy by Winkelmayer et al.8 It is not 
possible to interpret such ‘disagreement’ in the absence of a clear statement of the expected 
proportion of topics for which it is expected under the null hypothesis. Franklin et al. suggested an 
alternative based on comparing observed and expected overlap between confidence intervals, which 
Hemkens et al. described as “notoriously underpowered” and “clinically irrelevant.” In their 
correction, they discuss issues of power and Type I and II error rates associated with comparing 
expected versus observed overlap of CIs. I regret that they did not clarify levels of expected 
discrepancy associated with their own approach. 
This has been a bruising process for many of those concerned. Nonetheless, it has resulted in 
important clarifications about methods for empirical research on biases associated with study 
designs and characteristics. Such research has underpinned development of both reporting 
guidelines9 and tools to assess risk of bias10, and is of particular importance given the opportunities 
arising from availability of very large and detailed routine health care datasets, and the risks that 
analyses of such data lead to precise but misleading estimates of the effect of interventions. 
Jonathan Sterne, 25 July 2018 
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